Latest Ratios: P/E Ratio 1.6x · EV/EBITDA 2.6x · ROE 22.0%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $243M | $484M | $342M | $968M | $2.1B | $2.6B | $2.9B | $2.3B | $3.5B | $3.7B | $2.7B |
| Enterprise Value | $369M | $610M | $634M | $1.3B | $2.4B | $2.8B | $3.0B | $2.5B | $3.5B | $3.7B | $2.7B |
| P/E Ratio → | 1.58 | 3.03 | — | 114.24 | 20.37 | 17.74 | 15.05 | 13.22 | 28.39 | 28.91 | 18.74 |
| P/S Ratio | 0.16 | 0.33 | 0.20 | 0.49 | 0.96 | 0.97 | 1.12 | 0.95 | 1.29 | 1.64 | 1.21 |
| P/B Ratio | 0.31 | 0.60 | 0.53 | 1.18 | 2.37 | 2.86 | 3.22 | 2.62 | 4.43 | 5.31 | 4.04 |
| P/FCF | 5.29 | 10.52 | 4.88 | 16.10 | 43.47 | 35.77 | 9.14 | 20.49 | 26.17 | 15.44 | 11.91 |
| P/OCF | 3.03 | 6.03 | 3.06 | 8.16 | 19.71 | 18.43 | 7.60 | 12.88 | 17.08 | 12.37 | 9.74 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.41 | 0.37 | 0.67 | 1.07 | 1.03 | 1.15 | 1.02 | 1.31 | 1.63 | 1.24 |
| EV / EBITDA | 2.58 | 4.26 | — | 11.23 | 13.01 | 7.73 | 8.99 | 7.16 | 10.83 | 10.71 | 9.03 |
| EV / EBIT | 4.06 | 6.71 | — | 9.87 | 23.29 | 11.39 | 11.57 | 9.21 | 11.26 | 13.50 | 11.86 |
| EV / FCF | — | 13.25 | 9.03 | 21.94 | 48.69 | 38.02 | 9.45 | 22.02 | 26.50 | 15.28 | 12.18 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.4% | 69.4% | 68.2% | 68.9% | 71.7% | 75.0% | 74.5% | 76.0% | 76.3% | 78.0% | 77.3% |
| Operating Margin | 6.1% | 6.1% | -8.8% | 2.5% | 5.0% | 8.7% | 10.0% | 11.0% | 9.0% | 12.0% | 10.5% |
| Net Profit Margin | 10.8% | 10.8% | -8.5% | 0.4% | 4.7% | 5.5% | 7.4% | 7.2% | 4.5% | 5.7% | 6.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.0% | 22.0% | -19.9% | 1.0% | 11.6% | 16.3% | 21.6% | 20.9% | 16.4% | 18.9% | 19.2% |
| ROA | 11.1% | 11.1% | -9.0% | 0.5% | 5.6% | 7.6% | 10.3% | 10.0% | 7.4% | 8.4% | 9.6% |
| ROIC | 7.3% | 7.3% | -10.7% | 3.1% | 7.5% | 17.0% | 19.0% | 21.4% | 24.2% | 29.6% | 23.0% |
| ROCE | 7.9% | 7.9% | -11.4% | 3.3% | 7.8% | 16.8% | 18.2% | 20.1% | 20.1% | 24.8% | 21.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.45 | 0.45 | 0.73 | 0.74 | 0.58 | 0.55 | 0.56 | 0.58 | 0.55 | 0.55 | 0.63 |
| Debt / EBITDA | 2.54 | 2.54 | — | 5.17 | 2.84 | 1.40 | 1.51 | 1.47 | 1.33 | 1.12 | 1.37 |
| Net Debt / Equity | — | 0.16 | 0.45 | 0.43 | 0.29 | 0.18 | 0.11 | 0.20 | 0.06 | -0.05 | 0.09 |
| Net Debt / EBITDA | 0.88 | 0.88 | — | 2.99 | 1.40 | 0.46 | 0.29 | 0.50 | 0.13 | -0.11 | 0.20 |
| Debt / FCF | — | 2.73 | 4.15 | 5.84 | 5.22 | 2.25 | 0.31 | 1.53 | 0.33 | -0.16 | 0.27 |
| Interest Coverage | 6.52 | 6.52 | -5.63 | 5.23 | 4.68 | 22.13 | 19.66 | 13.93 | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.08 | 2.08 | 1.82 | 2.13 | 2.12 | 1.65 | 1.66 | 2.07 | 1.82 | 1.74 | 1.79 |
| Quick Ratio | 1.40 | 1.40 | 1.17 | 1.28 | 1.15 | 0.89 | 1.08 | 1.30 | 1.15 | 1.17 | 1.16 |
| Cash Ratio | 0.91 | 0.91 | 0.67 | 0.81 | 0.78 | 0.67 | 0.78 | 0.96 | 0.91 | 0.98 | 0.92 |
| Asset Turnover | — | 1.06 | 1.18 | 1.09 | 1.22 | 1.41 | 1.32 | 1.37 | 1.58 | 1.43 | 1.50 |
| Inventory Turnover | 2.54 | 2.54 | 2.89 | 2.19 | 1.82 | 1.69 | 2.09 | 2.11 | 2.14 | 1.98 | 2.00 |
| Days Sales Outstanding | — | 9.72 | 10.70 | 13.51 | 7.77 | 5.59 | 8.96 | 7.60 | 7.26 | 5.32 | 5.16 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 4.7% | 2.4% | 3.5% | 8.0% | 3.6% | 2.9% | 2.7% | 3.6% | 2.3% | 2.0% | 2.9% |
| Payout Ratio | 7.4% | 7.4% | — | 903.1% | 73.5% | 51.8% | 41.0% | 47.4% | 66.1% | 58.8% | 54.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 63.5% | 33.1% | — | 0.9% | 4.9% | 5.6% | 6.6% | 7.6% | 3.5% | 3.5% | 5.3% |
| FCF Yield | 18.9% | 9.5% | 20.5% | 6.2% | 2.3% | 2.8% | 10.9% | 4.9% | 3.8% | 6.5% | 8.4% |
| Buyback Yield | 8.2% | 4.1% | 0.6% | 1.3% | 3.3% | 3.1% | 5.0% | 0.0% | 2.0% | 1.9% | 9.2% |
| Total Shareholder Yield | 12.9% | 6.6% | 4.1% | 9.4% | 6.9% | 6.0% | 7.7% | 3.6% | 4.3% | 3.9% | 12.1% |
| Shares Outstanding | — | $50M | $50M | $50M | $51M | $51M | $53M | $56M | $56M | $55M | $56M |
Regulatory and distribution contraction
According to current market data, Nu Skin trades at a P/E of 1.65 and a P/S of 0.17, suggesting that investors are pricing in a permanent impairment of the company's long-term growth prospects rather than a temporary cyclical downturn in the direct-selling beauty sector.
The extremely low valuation multiples relative to historical averages and broader consumer defensive peers indicate that the market is heavily discounting the company's ability to stabilize its revenue base. This pricing suggests that investors may view the current dividend yield of 4.5% as a potential trap rather than a sustainable return, given the ongoing contraction in the active sales leader count.
As reported in recent financial statements, Nu Skin's ROIC has trended downward to 0.5% in 2026Q1, reflecting a significant decay in the company's ability to generate meaningful returns on its invested capital as the core business model faces persistent top-line headwinds and operational deleverage.
The sharp decline in ROIC from historical levels suggests that the company's investments in digital transformation, such as the Vera app, have yet to yield the productivity gains necessary to offset the erosion of the traditional direct-selling model. This trend warrants further investigation into whether the current capital allocation strategy is effectively supporting the business or merely subsidizing a shrinking operational footprint.
Based on the provided quarterly data, the cash conversion cycle has expanded to 142 days as of 2026Q1, indicating that Nu Skin is struggling with increasing inventory bloat and inefficient collection cycles as the company navigates a period of sustained revenue contraction across its core markets.
The elevated days inventory outstanding, which remains significantly higher than historical norms, suggests that the company may be experiencing channel stuffing or a mismatch between production levels and actual consumer demand. This inefficiency ties up critical liquidity and increases the risk of future inventory write-downs, further pressuring the company's already strained operating margins.
According to recent balance sheet filings, Nu Skin maintains a current ratio of 2.03, yet this headline figure obscures the underlying deterioration in cash generation, as the company's ability to fund operations internally has become increasingly compromised by negative free cash flow margins.
While the current ratio appears healthy on the surface, the reliance on cash reserves to fund dividends during a period of negative free cash flow suggests that the company's liquidity position is being depleted to maintain shareholder payouts. Investors should monitor whether this trend forces a reduction in capital returns or a shift in the company's conservative debt profile.
Based on an analysis of the company's business model, the P/E ratio is the most commonly misapplied metric, as it fails to account for the significant non-operating income and tax benefits that currently inflate net earnings and mask the underlying erosion of core operational profitability.
Analysts should instead focus on EV/EBITDA or free cash flow yield to better understand the company's true earning power, as these metrics strip away the noise of non-core items. Relying on P/E in this context may lead to a false sense of value, as it ignores the structural risks associated with the company's high commission-based cost structure and its heavy reliance on volatile international markets.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NUS stock.
Nu Skin Enterprises, Inc.'s current P/E ratio is 1.6x. The historical average is 21.5x.
Nu Skin Enterprises, Inc.'s current EV/EBITDA is 2.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 9.2x.
Nu Skin Enterprises, Inc.'s return on equity (ROE) is 22.0%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 24.8%.
Based on historical data, Nu Skin Enterprises, Inc. is trading at a P/E of 1.6x. Compare with industry peers and growth rates for a complete picture.
Nu Skin Enterprises, Inc.'s current dividend yield is 4.70% with a payout ratio of 7.4%.
Nu Skin Enterprises, Inc. has 69.4% gross margin and 6.1% operating margin.
Nu Skin Enterprises, Inc.'s Debt/EBITDA ratio is 2.5x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.